ZVSA vs. ALZN, ADTX, PTN, JAGX, ENTO, APVO, SCNI, GRTX, SXTP, and ONCO
Should you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Alzamend Neuro (ALZN), Aditxt (ADTX), Palatin Technologies (PTN), Jaguar Animal Health (JAGX), Entero Therapeutics (ENTO), Aptevo Therapeutics (APVO), Scinai Immunotherapeutics (SCNI), Galera Therapeutics (GRTX), 60 Degrees Pharmaceuticals (SXTP), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry.
ZyVersa Therapeutics vs. Its Competitors
ZyVersa Therapeutics (NASDAQ:ZVSA) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.
Alzamend Neuro has a consensus price target of $180.00, indicating a potential upside of 5,981.08%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than ZyVersa Therapeutics.
ZyVersa Therapeutics' return on equity of -109.54% beat Alzamend Neuro's return on equity.
ZyVersa Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.31, suggesting that its stock price is 131% less volatile than the S&P 500.
In the previous week, Alzamend Neuro had 3 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 5 mentions for Alzamend Neuro and 2 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.93 beat Alzamend Neuro's score of -0.28 indicating that ZyVersa Therapeutics is being referred to more favorably in the media.
3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Comparatively, 30.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Alzamend Neuro beats ZyVersa Therapeutics on 6 of the 11 factors compared between the two stocks.
Get ZyVersa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZyVersa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ZVSA) was last updated on 7/26/2025 by MarketBeat.com Staff
Free ZVSA Stock Alerts